• Rafael Holdings completed the last patient last visit in its pivotal Phase 3 TransportNPC study of Trappsol Cyclo for Niemann-Pick disease type C.
• Topline results have not been presented yet; release is expected in the second half of 2026.
• Pediatric sub-study data were previously presented at WORLDSymposium 2026, showing most patients improved or stayed stable with no drug-related serious safety issues.
• The company expects to submit a US NDA in the second half of 2026, following a pre-NDA meeting with the FDA.
• The FDA acknowledged that a US Expanded Access Program can proceed, supporting continued patient access ahead of potential approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rafael Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606100730PRIMZONEFULLFEED9734603) on June 10, 2026, and is solely responsible for the information contained therein.